New Opportunities for the Utilization of the Sulfoximine Group in Medicinal Chemistry from the Drug Designer's Perspective von Lücking, Ulrich

Volltext

Progress towards a public chemogenomic set for protein kinases and a call for contributions von Drewry, David H, Wells, Carrow I, Andrews, David M, Angell, Richard, Al-Ali, Hassan, Axtman, Alison D, Capuzzi, Stephen J, Elkins, Jonathan M, Ettmayer, Peter, Frederiksen, Mathias, Gileadi, Opher, Gray, Nathanael, Hooper, Alice, Knapp, Stefan, Laufer, Stefan, Luecking, Ulrich, Michaelides, Michael, Müller, Susanne, Muratov, Eugene, Denny, R Aldrin, Saikatendu, Kumar S, Treiber, Daniel K, Zuercher, William J, Willson, Timothy M

Volltext

Sulfoximines: A Neglected Opportunity in Medicinal Chemistry von Lucking, Ulrich

Volltext

Novel Pieces for the Emerging Picture of Sulfoximines in Drug Discovery: Synthesis and Evaluation of Sulfoximine Analogues of Marketed Drugs and Advanced Clinical Candidates von Sirvent, Juan Alberto, Lücking, Ulrich

Volltext

Abstract 3022: BAY 1143572, a first-in-class, highly selective, potent and orally available inhibitor of PTEFb/CDK9 currently in Phase I, shows convincing anti-tumor activity in pr... von Scholz, Arne, Oellerich, Thomas, Hussain, Akhtar, Lindner, Sarah, Luecking, Ulrich, Walter, Annette O., Ellinghaus, Peter, Valencia, Ray, von Nussbaum, Franz, Mumberg, Dominik, Brands, Michael, Ince, Stuart, Serve, Hubert, Ziegelbauer, Karl

Volltext

A New, Practical One‐Pot Synthesis of Unprotected Sulfonimidamides by Transfer of Electrophilic NH to Sulfinamides von Izzo, Flavia, Schäfer, Martina, Stockman, Robert, Lücking, Ulrich

Volltext

Exploration of Novel Chemical Space: Synthesis and in vitro Evaluation of N‐Functionalized Tertiary Sulfonimidamides von Izzo, Flavia, Schäfer, Martina, Lienau, Philip, Ganzer, Ursula, Stockman, Robert, Lücking, Ulrich

Volltext

The Novel ATR Inhibitor BAY 1895344 Is Efficacious as Monotherapy and Combined with DNA Damage-Inducing or Repair-Compromising Therapies in Preclinical Cancer Models von Wengner, Antje M, Siemeister, Gerhard, Lücking, Ulrich, Lefranc, Julien, Wortmann, Lars, Lienau, Philip, Bader, Benjamin, Bömer, Ulf, Moosmayer, Dieter, Eberspächer, Uwe, Golfier, Sven, Schatz, Christoph A, Baumgart, Simon J, Haendler, Bernard, Lejeune, Pascale, Schlicker, Andreas, von Nussbaum, Franz, Brands, Michael, Ziegelbauer, Karl, Mumberg, Dominik

Volltext

Increasing Complexity: A Practical Synthetic Approach to Three‐Dimensional, Cyclic Sulfoximines and First Insights into Their in Vitro Properties von Boulard, Emilie, Zibulski, Vivien, Oertel, Luisa, Lienau, Philip, Schäfer, Martina, Ganzer, Ursula, Lücking, Ulrich

Volltext

Synthesis of Highly Enantioenriched Sulfonimidoyl Fluorides and Sulfonimidamides by Stereospecific Sulfur–Fluorine Exchange (SuFEx) Reaction von Greed, Stephanie, Briggs, Edward L., Idiris, Fahima I. M., White, Andrew J. P., Lücking, Ulrich, Bull, James A.

Volltext

Changing for the Better: Discovery of the Highly Potent and Selective CDK9 Inhibitor VIP152 Suitable for Once Weekly Intravenous Dosing for the Treatment of Cancer von Lücking, Ulrich, Kosemund, Dirk, Böhnke, Niels, Lienau, Philip, Siemeister, Gerhard, Denner, Karsten, Bohlmann, Rolf, Briem, Hans, Terebesi, Ildiko, Bömer, Ulf, Schäfer, Martina, Ince, Stuart, Mumberg, Dominik, Scholz, Arne, Izumi, Raquel, Hwang, Stuart, von Nussbaum, Franz

Volltext

BAY 1000394, a novel cyclin-dependent kinase inhibitor, with potent antitumor activity in mono- and in combination treatment upon oral application von Siemeister, Gerhard, Lücking, Ulrich, Wengner, Antje M, Lienau, Philip, Steinke, Wolfram, Schatz, Christoph, Mumberg, Dominik, Ziegelbauer, Karl

Volltext

Damage Incorporated: Discovery of the Potent, Highly Selective, Orally Available ATR Inhibitor BAY 1895344 with Favorable Pharmacokinetic Properties and Promising Efficacy in Monot... von Lücking, Ulrich, Wortmann, Lars, Wengner, Antje M, Lefranc, Julien, Lienau, Philip, Briem, Hans, Siemeister, Gerhard, Bömer, Ulf, Denner, Karsten, Schäfer, Martina, Koppitz, Marcus, Eis, Knut, Bartels, Florian, Bader, Benjamin, Bone, Wilhelm, Moosmayer, Dieter, Holton, Simon J, Eberspächer, Uwe, Grudzinska-Goebel, Joanna, Schatz, Christoph, Deeg, Gesa, Mumberg, Dominik, von Nussbaum, Franz

Volltext

Identification of Atuveciclib (BAY 1143572), the First Highly Selective, Clinical PTEFb/CDK9 Inhibitor for the Treatment of Cancer von Lücking, Ulrich, Scholz, Arne, Lienau, Philip, Siemeister, Gerhard, Kosemund, Dirk, Bohlmann, Rolf, Briem, Hans, Terebesi, Ildiko, Meyer, Kirstin, Prelle, Katja, Denner, Karsten, Bömer, Ulf, Schäfer, Martina, Eis, Knut, Valencia, Ray, Ince, Stuart, von Nussbaum, Franz, Mumberg, Dominik, Ziegelbauer, Karl, Klebl, Bert, Choidas, Axel, Nussbaumer, Peter, Baumann, Matthias, Schultz‐Fademrecht, Carsten, Rühter, Gerd, Eickhoff, Jan, Brands, Michael

Volltext

The Lab Oddity Prevails: Discovery of Pan-CDK Inhibitor (R)-S-Cyclopropyl-S-(4-{[4-{[(1R,2R)-2-hydroxy-1-methylpropyl]oxy}-5-(trifluoromethyl)pyrimidin-2-yl]amino}phenyl)sulfoximid... von Lücking, Ulrich, Jautelat, Rolf, Krüger, Martin, Brumby, Thomas, Lienau, Philip, Schäfer, Martina, Briem, Hans, Schulze, Julia, Hillisch, Alexander, Reichel, Andreas, Wengner, Antje Margret, Siemeister, Gerhard

Volltext

Palladium-Catalyzed Direct α-Arylation of p-Methoxybenzyl-Protected S,S-Dimethylsulfoximine von Sirvent, Juan A., Bierer, Donald, Webster, Robert, Lücking, Ulrich

Volltext

The Kinase Chemogenomic Set (KCGS): An Open Science Resource for Kinase Vulnerability Identification von Wells, Carrow I, Al-Ali, Hassan, Andrews, David M, Asquith, Christopher R M, Axtman, Alison D, Dikic, Ivan, Ebner, Daniel, Ettmayer, Peter, Fischer, Christian, Frederiksen, Mathias, Futrell, Robert E, Gray, Nathanael S, Hatch, Stephanie B, Knapp, Stefan, Lücking, Ulrich, Michaelides, Michael, Mills, Caitlin E, Müller, Susanne, Owen, Dafydd, Picado, Alfredo, Saikatendu, Kumar S, Schröder, Martin, Stolz, Alexandra, Tellechea, Mariana, Turunen, Brandon J, Vilar, Santiago, Wang, Jinhua, Zuercher, William J, Willson, Timothy M, Drewry, David H

Volltext

Conformational Adaption May Explain the Slow Dissociation Kinetics of Roniciclib (BAY 1000394), a Type I CDK Inhibitor with Kinetic Selectivity for CDK2 and CDK9 von Ayaz, Pelin, Andres, Dorothee, Kwiatkowski, Dennis A, Kolbe, Carl-Christian, Lienau, Philip, Siemeister, Gerhard, Lücking, Ulrich, Stegmann, Christian M

Volltext

BAY-8400: A Novel Potent and Selective DNA-PK Inhibitor which Shows Synergistic Efficacy in Combination with Targeted Alpha Therapies von Berger, Markus, Wortmann, Lars, Buchgraber, Philipp, Lücking, Ulrich, Zitzmann-Kolbe, Sabine, Wengner, Antje M, Bader, Benjamin, Bömer, Ulf, Briem, Hans, Eis, Knut, Rehwinkel, Hartmut, Bartels, Florian, Moosmayer, Dieter, Eberspächer, Uwe, Lienau, Philip, Hammer, Stefanie, Schatz, Christoph A, Wang, Qiuwen, Wang, Qi, Mumberg, Dominik, Nising, Carl F, Siemeister, Gerhard

Volltext

Discovery of BAY-298 and BAY-899: Tetrahydro-1,6-naphthyridine-Based, Potent, and Selective Antagonists of the Luteinizing Hormone Receptor Which Reduce Sex Hormone Levels in Vivo von Wortmann, Lars, Lindenthal, Bernhard, Muhn, Peter, Walter, Alexander, Nubbemeyer, Reinhard, Heldmann, Dieter, Sobek, Lothar, Morandi, Federica, Schrey, Anna K, Moosmayer, Dieter, Günther, Judith, Kuhnke, Joachim, Koppitz, Marcus, Lücking, Ulrich, Röhn, Ulrike, Schäfer, Martina, Nowak-Reppel, Katrin, Kühne, Ronald, Weinmann, Hilmar, Langer, Gernot

Volltext